parallelogram_1
parallelogram_2
parallelogram_7

Leadership

OUR HISTORY

Clinical Ink was founded in 2007 by the late Tommy Littlejohn, M.D., and Doug Pierce, who both passionately believed that Clinical Ink’s solutions would revolutionize clinical research by eliminating paper source documentation — the last hurdle to paperless clinical trials. Long before the iPad, Tommy and Doug envisioned an innovative tablet-based software application that would offer site users the familiar look and feel of the paper source while allowing electronic capture, validation, and sharing for cleaner, faster data.

Clinical Ink’s co-founders leveraged valuable perspectives and a unique mix of expertise to build an organization that could realize this vision. Tommy brought more than 20 years of experience as a clinical investigator, and Doug brought another 20 years of experience running a medical forms publishing business. From 2007 to 2010, Tommy’s experience as an active researcher for over 3,000 studies served as an anchor and filter through which all software decisions would pass, making the positive impact that Clinical Ink solutions have on sites a core aim. Doug’s experience with medical form design was equally important in developing an intuitive user experience through an application interface that was often tested with actual site users. If the tablet wasn’t at least as fast and easy to use as paper, the interface would be redesigned, always with the goal of reducing site workload. Today, Tommy and Doug’s vision has become a reality, as Clinical Ink continues to revolutionize clinical research with our innovative Lunexis™ platform. Clinical Ink remains committed to our founders’ goals of dramatically reducing the cost and complexity of clinical research for sites, sponsors, and patients.

Our Leaders

Leadership Image

Ed Seguine

Chief Executive Officer

As chief executive officer (CEO), Ed Seguine brings more than 20 years of experience as a clinical technology executive at big pharma and start-up organizations to the Clinical Ink team. Mr. Seguine joined Clinical Ink in late 2009 with the goal of creating a company that would eliminate problems caused by current paper-based processes and technologies.

+

Prior to joining Clinical Ink, he served as general manager, trial planning at Medidata Solutions, where he managed acquisition integration activities and product positioning prior to the company’s IPO. He also served as CEO of Fast Track Systems, where he oversaw the turnaround process and established early commercial successes for a novel product that became the rationale for acquisition by Medidata Solutions. Prior to Fast Track, Mr. Seguine was a founding manager of the Eli Lilly & Co. venture capital funds, e.Lilly and Lilly Bioventures, focusing on technology and biotech and device companies. Mr. Seguine has also been intimately involved with key industry initiatives, including CDISC and eClinical Forum. He is a frequent presenter at industry events and publishes regularly. Mr. Seguine earned a master of business administration from Indiana University-Bloomington and a bachelor’s degree in finance from Brigham Young University.

-
Leadership Image

Doug Pierce

President & Co-Founder

Doug Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as president and co-founder, Mr. Pierce brings more than 20 years of experience in digital forms technology and mobile data capture to lead the strategic direction, development, and evolution of Clinical Ink’s eSource suite.

+

-
Leadership Image

Scott Miltenberger

Chief Financial Officer

As chief financial officer, Scott Miltenberger leads Clinical Ink’s accounting, business planning, and global financial operations. Mr. Miltenberger brings more than 20 years of financial management and technology industry experience, primarily in executive roles leading strategic global financial operations.

+

Prior to joining Clinical Ink, Mr. Miltenberger was chief financial officer for GPX Enterprises (GPX), a private equity firm focused on the sponsorship, development and management of selected investments, where he helped lead the company through a period of rapid growth. Prior to GPX, Mr. Miltenberger served as CFO for Elemica, a cloud-based software services company, where he led the company’s financial strategy and capital raising initiatives and was instrumental in the organization’s M&A activities. Prior to Elemica, he served as the founding CFO for a venture-backed healthcare services company and held a senior financial role at Novacare Employee Services, where he helped position the company for its IPO. Mr. Miltenberger began his career at Deloitte & Touche LLP. In addition to being a certified public accountant (CPA), Mr. Miltenberger holds a master of business administration in finance from Villanova University and a bachelor’s degree in economics and business from Lafayette College. He is active in many local business and youth sports organizations.

-
Leadership Image

Jonathan Andrus

Chief Business Officer

As chief business officer, Jonathan Andrus leads Clinical Ink’s solution management and commercial teams to help sponsors and CROs better leverage eSource, eCOA, and ePRO data. With more than 20 years of experience, Mr. Andrus brings extensive expertise developing eClinical services that integrate data and technology to help life science companies optimize study execution. At Clinical Ink, Mr. Andrus is responsible for P&L across Clinical Ink’s products and services, and he is also focused on building relationships and forging strategic partnerships with sponsors, CROs, regulatory bodies, and clinical research professionals.

+

Mr. Andrus joined Clinical Ink from Bioclinica where he led the eClinical Solutions Group to develop their current service offerings, including data management, quality management, implementation services, and IWRS. Prior to Bioclinica, Mr. Andrus worked in pharmaceutical consulting and with CROs focused on quality, data management, and validation. An active thought leader, blogger, and presenter, Jonathan served as chair of the Society for Clinical Data Management (SCDM) in 2008 and 2013 and currently serves as the society’s treasurer. He is also an active member of DIA (North American Advisory Council and Annual Conference Data/Data Standards Track Chair) and ASQ. He earned his bachelor’s and master’s degrees from Temple University’s College of Liberal Arts and Graduate School of Pharmacy and is a certified quality auditor (CQA) and certified clinical data manager (CCDM®).

-
Leadership Image

Vikram Natarajan

Chief Technology Officer

As chief technology officer, Vikram Natarajan leads Clinical Ink’s technology and product development operations. Mr. Natarajan brings more than 20 years of product development experience, primarily in health IT organizations leading the development of solutions for digital consumer health and patient engagement.

+

Prior to joining Clinical Ink, Mr. Natarajan was chief technology officer for PatientPay, a patient revenue cycle company that develops cutting-edge patient payment solutions. Prior to PatientPay, he served as the CTO for Medfusion, a venture-backed company that provided a patient engagement platform for hospitals and practices. He has also held senior leadership roles at different digital health and clinical research organizations like MDLIVE and Health Decisions.

-
Leadership Image

Chris Crucitti

Chief Commercial Officer

Chris Crucitti is a 20+ year seasoned life sciences and clinical services/technology executive. As chief commercial officer (CCO), Chris supports our continued growth, optimizing go-to-market strategies and building a scalable customer service approach.

+

Prior to joining Clinical Ink, Chris most recently held the role of CCO at Signant Health, leading commercial functions for their patient-centric clinical technology solutions. Chris brings significant experience and expertise in the clinical and R&D domains, including full-service CRO, data and analytics, eClinical technology solutions, strategic resourcing, consulting, and commercial. He has a track record of leading and building teams that drive significant revenue and profitability growth while maintaining a high level of customer service and quality delivery. Chris holds a master’s from American University and a bachelor’s from Ithaca College.

-
Leadership Image

Brian Donahue

Chief Operating Officer

As Clinical Ink’s chief operating officer (COO), Brian Donahue is responsible for leading the strategic direction and operations functions of the company as well as driving customer support across the organization. Brian will oversee the ongoing support of our customer base as well as ongoing data reporting while developing the strategy for shared services, project management, and operations functions across the business.

+

Prior to joining Clinical Ink, Brian held a variety of leadership roles at GE for 16 years, up to and including X-ray general manager for the U.S. and Canada, and central U.S. general manager and then commercial officer for the imaging business in the U.S. and Canada. Brian holds a bachelor’s degree in Political Science from West Virginia University.

-

Our Board

Ed Seguine

Chief Executive Officer

CEO

+

-

Vern Davenport

Partner, NovaQuest Capital Management

Vern Davenport brings more than 30 years of executive experience in building and transforming healthcare technology and service companies. Before joining NovaQuest, Mr. Davenport was CEO and board member at Medfusion, a leader in healthcare consumerism technology where he was instrumental in the carve-out of the company from Intuit and the return of its core portal solution to a market leadership position. Operationally, he created a culture that earned a Best Places to Work award from Triangle Business Journal. In less than twelve months, the company developed and released two new products in patient payments and consumer patient record integration leveraging both cloud and mobile technologies.

+

Prior to Medfusion, Mr. Davenport was chairman and CEO of Medquist and leader in transcription services before and after the privatization of the company. As chairman and CEO, Mr. Davenport facilitated a transformation of the business through the acquisition of a speech technology company, rebranding the company M*Modal and leading the take private process that resulted in the sale of the business to One Equity Partners. Mr. Davenport’s previous experience also includes his time as president of Allscripts, CEO of Misys Healthcare, GM and EVP of Kodak Health Group (now Carestream Health) and his time in executive leadership roles at Siemens Shared Medical Systems. Mr. Davenport began his career at IBM, where he spent eleven years in sales, sales leadership and executive management positions. Mr. Davenport received a master of business administration from East Carolina University as well as a bachelor of science in business administration. Mr. Davenport currently serves on the East Carolina Board of Trustees as well as the WakeMed Health and Hospitals board.

-

Michael Sorensen

Partner, NovaQuest Capital Management

Michael Sorensen brings more than 15 years of investment experience and is a member of the Investment Committee at NovaQuest Private Equity. He is responsible for transaction origination, investment policy, fundraising, investor relations and the day-to-day management of NovaQuest Private Equity. In addition, he directs the private equity team in acquisitions, divestitures and oversight of portfolio companies.

+

Prior to NovaQuest, Mr. Sorensen was director at BlackRock’s private equity group, responsible for making investment decisions in a wide variety of geographies and industries, including healthcare, technology and consumer and retail, among others. He also held a variety of board seats while at the firm. Prior to BlackRock, Mr. Sorensen worked at Sorenson Capital (no familial relation), a mid-market private equity firm based in Salt Lake City. Similar to his current role, he analyzed private companies in a wide range of industry sub sectors and geographies. Mr. Sorensen also worked as a consultant for L.E.K. Consulting in Los Angeles, where he worked closely with clients’ senior management on projects that included asset optimization, strategic planning and customer segmentation, primarily in the healthcare and media industries. Mr. Sorensen received a master of business administration from the Wharton School at the University of Pennsylvania, a master of public administration from Harvard University, and a bachelor of science in economics from Brigham Young University.

-

Dave Kreter

Managing Director, GI Partners

Dave Kreter is a managing director of GI Partners, with investment responsibilities for the company’s healthcare sector. Founded in 2001, GI Partners is a leading alternative investment management firm. It currently manages $2 billion dollars in capital commitments across multiple asset classes on behalf of highly respected institutional investors around the world. Mr. Kreter also serves on the boards of Generate Life Sciences, Netsmart Technologies, and GI's skilled nursing operator. Previously, he worked on investments in SoftLayer Technologies and the Telx Group, and served on the board of healthcare IT company Logibec and behavioral health provider AdvoServ.

+

Prior to joining GI Partners, he was with Francisco Partners in Menlo Park where he focused on private equity investments in the technology and healthcare industries, including the healthcare information technology (HCIT) business called Lynx Medical Systems. Earlier in his career, he worked in investment banking for Lehman Brothers' technology M&A group. Mr. Kreter holds an MBA from the Harvard Graduate School of Business and majored in economics for his undergraduate degree from Princeton University.

-

Mike Kirkman

Principal, GI Partners

Mike Kirkman is a principal at GI Partners. Mr. Kirkman has investment responsibilities for the company’s healthcare and technology and media and telecom (TMT) sectors. He currently also serves on the boards of MRI Software, Netsmart Technologies, and Generate Life Sciences. He is also a board observer for Logibec, one of Canada's largest healthcare IT companies specializing in providing clinical and administrative information systems.

+

Prior to joining GI Partners, Mr. Kirkman was with JLL Partners in New York where he focused on private equity investments in the North American healthcare and building products industries. Earlier in his career, he worked as an investment banker at J.P. Morgan and Houlihan Lokey in New York. He holds an MBA from the Wharton School of Business and received a Bachelor of Science degree from the McIntire School of Commerce, University of Virginia.

-

Nathan Lipkin

Vice President, GI Partners

Nathan Lipkin is a vice president at GI Partners. He currently serves on the board of Clinical Ink. Prior to rejoining GI Partners after business school, Mr. Lipkin was an investment banking analyst in the M&A group of Jefferies in New York.

+

Mr. Lipkin holds an MBA in healthcare management from the Wharton School of Business and a Bachelor of Science degree from the Medill School of Journalism at Northwestern University.

-

Connor McGauley

Vice President, Portfolio Operations, GI Partners

Connor McGauley is a vice president, portfolio operations, at GI Partners. He works with portfolio companies to accelerate growth and drives market diligence for potential investment. Mr. McGauley is on the boards of Clinical Ink and Blue Stream Fiber. Prior to joining GI Partners, he was the vice president of analytics and patient engagement for U.S. Anesthesia Partners, a Welsh, Carson, Anderson & Stowe portfolio company.

+

Prior to U.S. Anesthesia Partners, Mr. McGauley worked at Welsh, Carson, Anderson & Stowe, implementing best practice operating principles and continuous improvement programs across their portfolio of companies. Earlier in his career, he worked as a consultant across various industries including mining, financial services, and the public sector. Mr. McGauley holds a Bachelor of Commerce degree in accounting B.COMM from the University of British Columbia.

-

Roman Margolin

Independent Board Member/Advisor, Independent

Roman Margolin is an independent board member and advisor to healthcare and technology companies as well as an active angel/personal investor. Most recently, he was a managing director at Genstar Capital, one of the oldest private equity firms, managing approximately $20 billion of assets in software, healthcare, financial services, and industrial technology. At the firm for almost a decade, Mr. Margolin served on their investment committee and led their healthcare and technology practice. During his tenure, he led two of the largest realized investments in the firm’s history: ~$1 billion sale (4.4x return) of Netsmart and ~$2 billion dollar sale (8x return) of clinical trial technology company ERT. He was also a board member of PRA (Nasdaq: PRAH) and ConnectiveRx.

+

Prior to Genstar, Mr. Margolin co-founded a software startup incubated at Lightspeed Venture Partners. He was also an investment banker with JPMorgan and Brown Gibbons Lang, where he began his career two decades ago. He earned a bachelor’s in economics from Case Western Reserve University and an MBA from Stanford.

-

Our Partners

Contact the source of better clinical trials today.

Request a platform demo or more information.

Schedule a Demo